Key Efficacy Results From ADVANCE: MRD Negativity Stratified by Age and Risk

Panelists discuss how the ADVANCE study findings demonstrated high rates of minimal residual disease (MRD) negativity across both standard- and high-risk groups, reinforcing the potential of daratumumab-containing quadruplets to overcome adverse prognostic features. They highlight that MRD negativity correlated strongly with improved progression-free survival across age cohorts. The discussion notes that older patients also benefited, showing that advanced age alone should not preclude intensive therapy when performance status allows. The data suggest a meaningful narrowing of efficacy gaps between risk categories, supporting continued use of MRD as a dynamic end point for therapy adjustment.